RESEARCH ARTICLE

Genome-wide CRISPR screening identifies new regulators of glycoprotein secretion [version 1; peer review: 2 approved with reservations]

Stephanie Popa 1, Julien Villeneuve 1, Sarah Stewart 1, Esther Perez Garcia 2, Anna Petrunkina Harrison 2, Kevin Moreau 1

1 University of Cambridge Metabolic Research Laboratories, Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, CB2 0QQ, UK
2 NIHR Cambridge BRC Cell Phenotyping Hub, Department of Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK

Abstract

**Background:** The fundamental process of protein secretion from eukaryotic cells has been well described for many years, yet gaps in our understanding of how this process is regulated remain.

**Methods:** With the aim of identifying novel genes involved in the secretion of glycoproteins, we used a screening pipeline consisting of a pooled genome-wide CRISPR screen, followed by secondary siRNA screening of the hits to identify and validate several novel regulators of protein secretion.

**Results:** We present approximately 50 novel genes not previously associated with protein secretion, many of which also had an effect on the structure of the Golgi apparatus. We further studied a small selection of hits to investigate their subcellular localisation. One of these, GPR161, is a novel Golgi-resident protein that we propose maintains Golgi structure via an interaction with golgin A5.

**Conclusions:** This study has identified new factors for protein secretion involved in Golgi homeostasis.

**Keywords**

secretion, CRISPR screen, Golgi, endoplasmic reticulum
Corresponding author: Kevin Moreau (kevin.moreau@astrazeneca.com)

Author roles: Popa S: Conceptualization, Formal Analysis, Funding Acquisition, Investigation, Methodology, Validation, Visualization, Writing – Original Draft Preparation; Villeneuve J: Investigation, Methodology, Validation, Visualization, Writing – Review & Editing; Stewart S: Data Curation, Funding Acquisition, Writing – Review & Editing; Perez Garcia E: Methodology, Writing – Review & Editing; Petrunkina Harrison A: Funding Acquisition, Methodology, Writing – Review & Editing; Moreau K: Conceptualization, Formal Analysis, Funding Acquisition, Investigation, Methodology, Project Administration, Resources, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This work was supported by a Wellcome Trust PhD studentship for S.J.P. [109152], a Wellcome Trust Strategic Award [100574], the Medical Research Council Metabolic Diseases Unit [MRC_MC_UU_12012/5], the Isaac Newton Trust/Wellcome Trust ISSF/University of Cambridge joint research grant for J.V. and K.M., Biotechnology and Biological Science Research Council Future Leader Fellowship for S.E.S and the National Institute for Health Research for E.P.G. and A.P.H.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2019 Popa S et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Popa S, Villeneuve J, Stewart S et al. Genome-wide CRISPR screening identifies new regulators of glycoprotein secretion [version 1; peer review: 2 approved with reservations] Wellcome Open Research 2019, 4:119 (https://doi.org/10.12688/wellcomeopenres.15232.1)

Introduction

Protein secretion is a fundamental and well-known process in cell biology, in which proteins are transported from the endoplasmic reticulum (ER) to the Golgi via coat protein-coated vesicles and subsequently to the plasma membrane1–2. The localisation and activity of proteins involved in this secretory pathway must be tightly regulated to ensure correct spatiotemporal distribution of membranes and cargo proteins along the pathway. While the molecular machinery of secretion is relatively well understood, our knowledge remains incomplete, particularly regarding the regulation of protein secretion. For example, evidence suggests that multiple trafficking routes for transport within the Golgi exist3. The complex process of sorting proteins at the Golgi into vesicles for their correct destinations also requires further investigation3–5.

Recently, genome-wide CRISPR screening has emerged as a powerful strategy to identify novel gene functions; this type of screening has the advantages of being unbiased and more reliable than previously-used methods, in terms of introducing genetic mutations6. As such, it provides an opportunity to uncover new information about the regulation of protein secretion. Pooled CRISPR screening has been used for a wide range of applications, including the investigation of drug-resistance mechanisms in cancer cells7, the genetics of pluripotency8, autophagy regulators9,10 and host factors required for viral infection11. We previously demonstrated that unbiased pooled genome-wide CRISPR screening could effectively reveal key players required for glycoprotein secretion, using galectin-3 retention at the cell surface to assess glycoprotein secretion12. Galectin-3 is a cytosolic protein that is secreted without entering the conventional secretory pathway for its export to the extracellular space. Vesicular and non-vesicular modes of secretion have been proposed, but the precise series of events involved in the unconventional secretion of galectin-3 remain ill defined13. Once outside the cell, galectin-3 binds to β-galactosides resident on the cell surface14 and can therefore be used as an indirect measure of glycoprotein transport to the cell surface via the ER-Golgi secretory pathway. Using a binding partner of glycans as a readout, rather than one specific glycoprotein, allows regulators of general glycoprotein secretion to be discovered.

Here, we devised a powerful experimental pipeline, using an improved pooled genome-wide CRISPR screen, followed by two arrayed secondary screening methods using siRNA knockdown to identify new factors involved in glycoprotein secretion and Golgi apparatus architecture. Combining these methods allows the speed and reduced cost of pooled CRISPR screening to be taken together with the advantages of an arrayed siRNA screen in which genotype and phenotype remain linked15. Using this approach, we were able to validate 55 novel hits that are important for glycoprotein secretion. We found that many of these hits are also important for maintenance of the Golgi architecture. One of these hits, GPR161, is a novel Golgi-localised protein that decreases glycoprotein secretion and disrupts the Golgi structure.

Methods

Cell culture

HeLa cells, suspension HeLa cells expressing Cas9 (sHeLa-Cas9) and HeLa cells expressing horseradish peroxidase fused to a signal sequence to direct its secretion (HeLa-ss-HRP) were cultured in 10% culture medium: 10% (v/v) FBS, 100 U Penicillin / 0.1 mg ml⁻¹ streptomycin, 2 mM L-glutamine in high glucose DMEM, in 5% CO₂ at 37°C. See Table 1 for a list of all reagents used and their sources.

CRISPR screen: transduction with Brunello library

24 h before transduction, suspension HeLa cells were passaged. The lentiviral Brunello library, which targets 19,114 genes in the human genome with four unique guides per gene16, was used to transduce 1 × 10⁶ suspension HeLa cells expressing Cas9 (sHeLa-Cas9) in polybrene media (10 µg ml⁻¹ polybrene, 10% (v/v) FBS, 100 U Penicillin / 0.1 mg ml⁻¹ streptomycin, 2 mM L-glutamine in high glucose DMEM (Sigma, D6546)) at an MOI of 0.50 by spinoculation at 1000 × g for 30 min at 20°C. This gave a transduction efficiency of 40% and therefore an overall percentage of 31% cells with one guide per cell, as calculated using the Poisson distribution for the probability that a cell will be infected with at least one virus, 1− P(0, MOI)17. Cells were incubated for 24 h at 37°C, 5% CO₂ before passage into puromycin media (1 µg ml⁻¹ puromycin, 10% (v/v) FBS, 100 U Penicillin / 0.1 mg ml⁻¹ streptomycin, 2 mM L-glutamine in high glucose DMEM). Cells were cultured in puromycin media for seven days to retain only transduced cells. The transduction efficiency was measured as the percentage of live cells after 48 h in puromycin media.

CRISPR screen: cell sorting by flow cytometry

Cells were washed once with DMEM, incubated with 50 µg ml⁻¹ anti-galectin-3 antibody conjugated to Alexa Fluor 647 for 30 min at 4°C, then washed again. Approximately 3 × 10⁵ cells were sorted into the NIH CRISPR Cell Phenotypic Hub (BD Biosciences) using a BD FACS Aria III cell sorter. Target cell population to be sorted was gated based on the lowest anti-galectin-3-AF647 fluorescent signal, using Purity as sort precision mode. After cell sorting, cells were cultured in 20% serum media for 24–48 h, then cultured in culture media. When the population had expanded to 5 × 10⁶ cells, two samples were taken; 5 × 10⁵ cells were frozen for guide sequencing, and 1 × 10⁶ were assessed by flow cytometry. Gating leniency was decreased with progressive rounds, as shown in Figure 1. After the third sort, two distinct negative populations were observed, so a fourth sort was performed to separate these two populations, gating each population around a 5–10% peak. For flow cytometry of 1 × 10⁶ cells after cell sorting, cells were immunostained as above, with an additional propidium iodide stain for 5 min, and analysed on an Accuri C6 (BD Biosciences) equipped with lasers providing 488 nm and 640 nm excitation sources. Alexa Fluor 647 fluorescence was detected with an FL4 detector (675/25 BP).
### Table 1. List of reagents.

<table>
<thead>
<tr>
<th>Reagent or resource</th>
<th>Source</th>
<th>Identifier</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antibodies</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rat anti-galectin-3-647 mAb</td>
<td>BioLegend</td>
<td>125408, RRID: AB_1186110</td>
</tr>
<tr>
<td>Sheep anti-TGN46 pAb, IF concentration 5 µg ml⁻¹</td>
<td>BioRad</td>
<td>AHP500, RRID: AB_324049</td>
</tr>
<tr>
<td>Mouse anti-GM130 mAb, IF concentration 25 µg ml⁻¹</td>
<td>BD Biosciences</td>
<td>610822, RRID: AB_398141</td>
</tr>
<tr>
<td>Mouse anti-Sec31 mAb, IF concentration 25 µg ml⁻¹</td>
<td>BD Biosciences</td>
<td>612351, RRID: AB_39971</td>
</tr>
<tr>
<td>Mouse anti-MHC-I mAb, IF concentration 20 µg ml⁻¹</td>
<td>ThermoFisher</td>
<td>MA1-70111, RRID: AB_1076705</td>
</tr>
<tr>
<td>Rabbit anti-calmexin pAb, IF concentration 5 µg ml⁻¹</td>
<td>Abcam</td>
<td>ab22595, RRID: AB_2801328</td>
</tr>
<tr>
<td>Rabbit anti-GPR161 pAb, IF concentration 10 µg ml⁻¹</td>
<td>MyBioSource</td>
<td>MBS719938, RRID: AB_2801289</td>
</tr>
<tr>
<td>Rabbit anti-TMEM220 pAb, IF concentration 100 µg ml⁻¹</td>
<td>Aviva Systems Biology</td>
<td>ARP44467_P050, RRID: AB_2801328</td>
</tr>
<tr>
<td>Rabbit anti-Golgin A5 pAb, IF concentration 10 µg ml⁻¹</td>
<td>GeneTex</td>
<td>GTX104255, RRID: AB_2037117</td>
</tr>
<tr>
<td>Donkey anti-sheep IgG-568 pAb, IF concentration 4 µg ml⁻¹</td>
<td>ThermoFisher</td>
<td>A21099, RRID: AB_2535753</td>
</tr>
<tr>
<td>Goat anti-mouse IgG-488 pAb, IF concentration 4 µg ml⁻¹</td>
<td>ThermoFisher</td>
<td>A11001, RRID: AB_2534069</td>
</tr>
<tr>
<td>Goat anti-rabbit IgG-568 pAb, IF concentration 4 µg ml⁻¹</td>
<td>ThermoFisher</td>
<td>A11011, RRID: AB_143157</td>
</tr>
<tr>
<td>Mouse anti-FLAG M2 mAb, IF concentration 0.5 µg ml⁻¹</td>
<td>Sigma</td>
<td>F1804, RRID: AB_262044</td>
</tr>
<tr>
<td><strong>Cell lines</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HeLa</td>
<td>ATCC</td>
<td>CCL-2</td>
</tr>
<tr>
<td>HeLa-HRP</td>
<td>Gift from Vivek Malhotra</td>
<td>As described⁹</td>
</tr>
<tr>
<td>sHeLa (HeLa S3)</td>
<td>Gift from Paul Lehner</td>
<td>Sigma, 87110901</td>
</tr>
<tr>
<td>sHeLa-Cas9</td>
<td>In house production</td>
<td>As described¹¹</td>
</tr>
<tr>
<td><strong>Genome-wide screen library</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lentiviral Brunello</td>
<td>David Root and John Doench, Addgene</td>
<td>73178-LV</td>
</tr>
<tr>
<td><strong>Plasmids</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mouse-GPR161-FLAG</td>
<td>Insight Biotechnology LTD</td>
<td>MR224248</td>
</tr>
<tr>
<td>Human-TMEM220-FLAG</td>
<td>Genescript USA INC</td>
<td>OHu14539</td>
</tr>
<tr>
<td>Human-COL14A1-FLAG</td>
<td>Stratech Scientific LTD</td>
<td>HG13622-CF-SIB</td>
</tr>
<tr>
<td>Mouse-FAM98B-FLAG</td>
<td>Insight Biotechnology LTD</td>
<td>MR206836</td>
</tr>
<tr>
<td>Mouse-FAM102B-FLAG</td>
<td>Insight Biotechnology LTD</td>
<td>MR212923</td>
</tr>
<tr>
<td>Mouse-MXRA7-FLAG</td>
<td>Insight Biotechnology LTD</td>
<td>MR218215</td>
</tr>
<tr>
<td><strong>Software</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MaGECK</td>
<td><a href="https://sourceforge.net/p/mageck/wiki/Home/">https://sourceforge.net/p/mageck/wiki/Home/</a></td>
<td>Version 0.5.7</td>
</tr>
<tr>
<td>MaGECK-vispr</td>
<td><a href="https://bitbucket.org/liulab/mageck-vispr">https://bitbucket.org/liulab/mageck-vispr</a></td>
<td>Version 0.5.3</td>
</tr>
<tr>
<td>GraphPad PRISM</td>
<td>GraphPad</td>
<td>Version 7</td>
</tr>
<tr>
<td>GO term mapper</td>
<td><a href="https://go.princeton.edu/cgi-bin/GOTermMapper">https://go.princeton.edu/cgi-bin/GOTermMapper</a></td>
<td>Accessed 7th Jan 2019</td>
</tr>
<tr>
<td>CellProfiler</td>
<td><a href="http://cellprofiler.org/releases/">http://cellprofiler.org/releases/</a></td>
<td>Version 3.1.5</td>
</tr>
<tr>
<td>CellProfiler Analyst</td>
<td><a href="http://cellprofiler.org/releases/">http://cellprofiler.org/releases/</a></td>
<td>Version 2.2.1</td>
</tr>
<tr>
<td>Fiji</td>
<td><a href="https://imagej.net/Fiji/Downloads">https://imagej.net/Fiji/Downloads</a></td>
<td>ImageJ-win64, downloaded 25th May 2018</td>
</tr>
<tr>
<td>R</td>
<td><a href="https://www.r-project.org/">https://www.r-project.org/</a></td>
<td>Version 3.5.1</td>
</tr>
<tr>
<td>Reagent or resource</td>
<td>Source</td>
<td>Identifier</td>
</tr>
<tr>
<td>-------------------------------------</td>
<td>--------------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>High glucose Dulbecco’s Modified Eagle Medium (DMEM)</td>
<td>Molecular Probes</td>
<td>D6546</td>
</tr>
<tr>
<td>Hank’s Balanced Salt Solution (HBSS)</td>
<td>ThermoFisher</td>
<td>14025092</td>
</tr>
<tr>
<td>Fetal bovine serum (FBS)</td>
<td>ThermoFisher</td>
<td>10270-106</td>
</tr>
<tr>
<td>L-glutamine</td>
<td>Sigma</td>
<td>G7513</td>
</tr>
<tr>
<td>Penicillin/streptomycin</td>
<td>Sigma</td>
<td>P0781</td>
</tr>
<tr>
<td>Polybrene</td>
<td>Merck</td>
<td>TR-1003-G</td>
</tr>
<tr>
<td>Dulbecco’s Modified Eagle Medium (DMEM)</td>
<td>Life Technologies</td>
<td>21063-029</td>
</tr>
<tr>
<td>Propidium iodide</td>
<td>Biolegend</td>
<td>421301</td>
</tr>
<tr>
<td>Gentra Puregene Cell kit</td>
<td>Qiagen</td>
<td>158388</td>
</tr>
<tr>
<td>dNTP</td>
<td>ThermoFisher</td>
<td>R0191</td>
</tr>
<tr>
<td>ExTaq</td>
<td>Takara</td>
<td>RR001B</td>
</tr>
<tr>
<td>AMPure XP magnetic beads</td>
<td>Beckman Coulter</td>
<td>A63880</td>
</tr>
<tr>
<td>White 96 well CulturPlate</td>
<td>PerkinElmer</td>
<td>6005680</td>
</tr>
<tr>
<td>96 well ViewPlate</td>
<td>PerkinElmer</td>
<td>6005182</td>
</tr>
<tr>
<td>PBS</td>
<td>ThermoFisher</td>
<td>D8537</td>
</tr>
<tr>
<td>ProLong with DAPI</td>
<td>Invitrogen</td>
<td>P36962</td>
</tr>
<tr>
<td>Paraformaldehyde</td>
<td>Sigma</td>
<td>158127</td>
</tr>
<tr>
<td>TransIT 2020</td>
<td>Mirus</td>
<td>MIR 5405</td>
</tr>
<tr>
<td>Lipofectamine 2000</td>
<td>ThermoFisher</td>
<td>12566014</td>
</tr>
<tr>
<td>Phalloidin Green</td>
<td>ThermoFisher</td>
<td>A12379</td>
</tr>
<tr>
<td>ProLong Gold with DAPI</td>
<td>ThermoFisher</td>
<td>P36935</td>
</tr>
<tr>
<td>Tween 20</td>
<td>Sigma</td>
<td>P1379</td>
</tr>
<tr>
<td>ECL Western Blotting Detection Reagent</td>
<td>Amersham</td>
<td>RPN2106</td>
</tr>
<tr>
<td>Westar XLS100</td>
<td>Cyanagen</td>
<td>XLS100</td>
</tr>
<tr>
<td>Restore Plus</td>
<td>ThermoFisher</td>
<td>46430</td>
</tr>
</tbody>
</table>

### Primers and siRNA

<table>
<thead>
<tr>
<th></th>
<th>Source</th>
<th>Identifier</th>
</tr>
</thead>
<tbody>
<tr>
<td>P5 primer mix</td>
<td>Integrated DNA Technologies</td>
<td>See Extended data, E2(^\text{22})</td>
</tr>
<tr>
<td>P7 primers</td>
<td>Integrated DNA Technologies</td>
<td>See Extended data, E3(^\text{22})</td>
</tr>
<tr>
<td>siGenome smart pool plate</td>
<td>Dhharmacon</td>
<td>G-CUSTOM-384690 (see Extended data, E4)(^\text{22})</td>
</tr>
</tbody>
</table>

**CRISPR screen: Library preparation and sequencing**

To prepare samples for sequencing, genomic DNA from the different cell populations was extracted from frozen cell pellets using Gentra Puregene Cell kit and concentration of DNA was measured on the Nanodrop. PCR was carried out in quadruplicate to amplify an amplicon containing the guide, with primers used to attach barcodes, stagger regions and sequencing adaptors for use in sequencing, as previously described by Doench et al.\(^\text{18}\). Briefly, each well was set up to contain 10 µg genomic DNA, 0.5 µM uniquely barcoded P7 primer, 0.5 µM P5 stagger primer mix, 200 µM each dNTP, 7.5 units ExTaq and 1x ExTaq buffer in a total volume of 100 µl. PCR cycles were: initial denaturation step at 95°C for 1 min; 28 cycles of 95°C for 30 s, 53°C for 30 s, 72°C for 30s; final extension at 72°C for 10 min. One replicate from each sample was analysed on a 2% agarose gel to confirm amplification was successful. PCR products were pooled, adding 30 µl from each PCR reaction, then purified using AMPure XP magnetic beads to retain only DNA fragments larger than 100 bp\(^\text{18}\). An equal volume of the pooled product and AMPure XP magnetic beads were mixed at room temperature for 5 min, then placed on a magnet to retain beads. Beads were washed three times with 70% ethanol and purified PCR product was eluted with 500 µl EB buffer. Sequencing was carried out by the CRUK genomics facility using SE50 sequencing on the Illumina HiSeq 4000.

**CRISPR screen: Bioinformatics analysis using MaGECK**

Data were analysed using both MaGECK-MLE\(^\text{23}\) and MaGECK-RRA\(^\text{24}\) (version 0.5.7), using an enrichment (positive) sort type. In all analyses, median normalisation was used. PCR
Figure 1. CRISPR screen. (A) Workflow of genome-wide CRISPR screen. (B) Multiple rounds of cell sorting by flow cytometry, decreasing gating percentage with progressive rounds, resulted in final populations of cells with a low level of galectin-3 on the cell surface. FACS plots are of samples taken after cells had been expanded after cell sorting, and show cell surface galectin-3 levels as measured by anti-galectin-3-647 fluorescence, and viability as measured by PI. Labels of FACS plots refer to population names: N1-4 = populations after negative sorts 1–4; M4, cells expressing medium level of galectin-3 after sort 4. (C) Hits from populations N1 and N4; genes with a false discovery rate (FDR) <0.5 were defined as hit and shown in red. Genes with had guides that were enriched, but not significantly enriched (i.e. FDR ≥ 0.5), are shown in grey. (D) Euler diagram showing the number of hits known to be associated with organelles in the secretory pathway. Many ER-resident hits are lost when progressing from sorts N1 to N4. (E) Heat map of genes known to be in the secretory pathway, glycosylation pathway or involved in protein transport, as annotated by GO_Slim lists. Grey indicates an FDR greater than 0.5; hits are shown on a white-red scale, where darker red indicates a more significant FDR, closer to 0. The identity of hits changes significantly from populations N1 to N4.
replicates were treated as technical replicates and sort replicates were treated as biological replicates. Each population was given an identification code; descriptions are available in data file S2 (see Underlying data)\textsuperscript{25}. Genes were annotated with their function using UniProt\textsuperscript{26}, and with the organelle they reside in using Gene Ontology subsets\textsuperscript{6,27}.

**Secondary screen: HRP assay**

Based on having an unknown or unclear function in secretion, hits from the MaGECK analyses were selected to create a shortlist of 368 genes to be used in a secondary screen. This shortlist was screened in an arrayed siRNA screen, using siGenome smart pools (Dharmacon) in which each plate contained two replicates of non-targeting siRNA as a negative control. To screen for conventional secretion, HeLa cells expressing ss-HRP were reverse transfected in with the secondary screen library, as previously described\textsuperscript{28}. Briefly, 80 µl of 31 000 cells ml\textsuperscript{-1} were plated into wells of a 96 well plate containing a mixture of 20 µl 250 nM siRNA and 0.5% (v/v) lipofectamine 2000 in OptiMEM and incubated at 37°C, 5% CO\textsubscript{2}. Medium was changed to fresh culture medium 48 h after transfection. 72 h after transfection both supernatants and cell lysates were assessed for HRP levels in white CulturPlate 96 well plates by chemiluminescence using a Tecan M1000 Pro. Luminescence signal from the cell lysate (CL), supernatant (SN) and the CL:SN ratio were each normalised to signal obtained from siRNA control cells according to the formula:

\[
\frac{x - \text{mean background}}{\text{mean siRNA control} - \text{mean background}}
\]

To identify genes required for HRP secretion, a line with a gradient of 1 was fit to the normalised CL vs normalised SN data. Outliers of this line, as identified by the ROUT method\textsuperscript{29}, are genes that result in an up or down regulation of HRP secretion. The same method was also used to identify outliers from the line of y = 1 for the normalised CL:SN ratio line. The Gene Ontology (GO) Term Mapper was used to classify hits identified into broad categories, using the ontology aspect “process” and ontology category “Generic slim” (GO_Slim) for Homo sapiens (GOA @EBI + Ensembl) proteins\textsuperscript{30}. A gene was defined as related to protein transport if it was annotated with any of the GO_Slim annotations: transport (GO:0006810), transmembrane transport (GO:0055085) or vesicle-mediated transport (GO:0016192).

**Secondary screen: Golgi morphology**

HeLa cells were reverse-transfected as described above, although here transfected in 96-well ViewPlates. At 72 h after transfection, cells were fixed in ice cold methanol for 5 min, washed in PBS, stained with appropriate primary and secondary antibodies and ProLong with DAPI, and observed using an Opera Phenix High-Content Screening System to obtain unbiased confocal pictures. Analysis was performed on CellProfiler\textsuperscript{31} (version 3.1.5) to define cells and Golgi, and to measure Golgi intensity, size, shape and granularity. Briefly, cells were defined as secondary objects by propagation from nuclei, using a global “minimum cross entropy” thresholding method. Golgi were defined within a broad pixel diameter range of 2-60 px, and using an adaptive, two-class, Otsu thresholding method. The classifier of CellProfiler Analyst (CPA)\textsuperscript{32} (version 2.2.1) was then trained using cells randomly chosen from the whole experiment. These were classified as having fragmented or intact Golgi until the sensitivity reached an acceptable level: 82% and 77% for the intact Golgi and fragmented Golgi classes, respectively; here, 65 cells were used. The CPA classifier was then used to define all cells as having intact or fragmented Golgi.

**Immunofluorescence microscopy**

For immunofluorescence microscopy, cells were cultured on coverslips, fixed with either 4% parafomaldehyde in PBS for 5 min and permeabilised with 0.1% Triton X100 in PBS for 5 min, or fixed and permeabilised with ice cold methanol for 5 min. Cells were then blocked in 10% (v/v) FBS / 1x PBS for 2 h, washed three times with PBS, and incubated with secondary antibodies for 30 min. Primary and secondary antibodies, and the concentration they were used at for immunofluorescence, are listed in Table 1. Samples were mounted using ProLong Gold anti-fade reagent with DAPI and observed using a Leica SP8 laser confocal microscope.

**Analysis of hits**

To find interacting partners of proteins of interest, we used the BioPlex network, a resource of proteins shown to interact by affinity purification-mass spectrometry\textsuperscript{33,34}. Default parameters were used to search the network.

**Co-localisation analysis**

To measure co-localisation between golgin A5 and TGN46, 17 cells were selected from each treatment from confocal micrographs and analysed using the coloc 2 plugin in Fiji (downloaded 25\textsuperscript{th} May 2018)\textsuperscript{35}. For cells with TMEM220 or GPR161 knocked down, only cells with fragmented Golgi were selected from confocal micrographs to be confident that siRNA knockdown was effective. Pearson’s coefficient with no threshold was recorded for each cell analysed. Data were tested for normality and equality of variance by the Shapiro-Wilk test and Bartlett’s K squared test, respectively. After passing normality tests, data were analysed by one-way ANOVA followed by Tukey HSD post-hoc test between groups. All statistical analysis was performed using R (version 3.5.1).

An earlier version of this article can be found on bioRxiv, DOI: https://doi.org/10.1101/522334.
Results

A genome-wide CRISPR screen revealed novel regulators of glycoprotein secretion

We carried out a genome-wide CRISPR screen with the aim of identifying novel genes involved in glycoprotein secretion, using the level of galectin-3 on the surface of live cells to look at glycoprotein secretion via the ER-Golgi pathway. The workflow for the screen is shown in Figure 1A. Suspension HeLa cells stably expressing Cas9 were transduced with the Brunello lentiviral guide (sgRNA) library, an optimised library for the human genome,4 at a low multiplicity of infection such that the majority of the transduced cells received exactly one sgRNA. After transduction, we performed three rounds of cell sorting by fluorescence activated with increasing selection stringency for low levels of cell surface galectin-3. This method initially allows more cells through cell sorting, then becomes gradually more stringent by decreasing the gating percentage, increasing the number of true positives in later sorted populations. This resulted in the enrichment of two distinct populations with low levels of cell-surface galectin-3 after the third sort, in population N3 (Figure 1B). As there are lots of cells with very little or no galectin-3 on the cell surface in population N3, the other populations may have more galectin-3, transferred from the extracellular pool, or a higher effective concentration of anti-galectin-3 antibody. A fourth round of cell sorting was used to separate these distinct populations, resulting in populations M4 and N4 (Figure 1B). We extracted genomic DNA from all populations and carried out deep sequencing to determine the raw sgRNA counts in each population, available in data file S1 (see Underlying data).5 MaGECK analysis allowed the identification of hits from population N1 onwards; full MaGECK results are available in data file S2 (see Underlying data).6 Hits enriched in populations N1 and N4 are shown in Figure 1C.

The identity of the hits changed as cell sorting progressed. This was particularly true of hits which localise to the ER; in total, 64 hits localise to the ER in population N1, compared to 29 in population N4 (Figure 1D). As many genes in the ER are involved in critical biological processes, it is likely that these genes were lost in later sorts as cells lacking these genes have a growth or survival defect. For example, many of the enzymes involved in N-linked glycosylation, such as the asparagine-linked glycosylation (ALG) enzymes ALG1, ALG3, ALG5, ALG6 and ALG8, are identified as hits in population N1 but are lost in N4. Conversely, some hits are enriched after multiple cell sorting rounds in N4 but were not identified in N1 (Figure 1E). As such, we took a selection hits from across all populations forward into the secondary screen. MaGECK-MLE and MaGECK-RRA analysis revealed that there is little difference between the later populations: N3, M4 and N4 (data file S2, see Underlying data).7 As we intended to validate hits with further screening, we used a false discovery rate (FDR) of 0.5 to classify hits. This lenient FDR is validated by the presence of hits previously shown to play a role in secretory and glycosylation pathways, such as ribosomal proteins involved in protein translation into the ER machinery, enzymes involved in N-linked glycosylation, RAB proteins and trafficking protein particle complex (TRAPPC) proteins (Figure 1E). This shows that our screen was very efficient in identifying previously described regulators of glycoprotein secretion. Additionally, there were many hits identified that did not have a clear link to functions in protein secretion. Therefore, we hypothesised that many genes enriched in our screen with either no characterised function, or with no described function in the secretory pathway, may be new regulators of protein secretion.

An RNAi secondary screen validated hits from the CRISPR screen

Due to the lenient FDR used for MaGECK, it was important to validate the hits. Around 400 hits, identified from populations N1 - N4/M4 of the CRISPR screen, were selected for validation by secondary screening. Of these 400 hits, 113 had no annotated function in UniProt; 32 also had no GO annotations. As many of these hits were uncharacterised, they had the potential to represent novel regulators of protein secretion. Twelve positive controls annotated with GO terms related to protein secretion were also included in the screen to validate the statistical analysis. For secondary screening, we used siRNA knockdown of hits in HeLa cells that stably express ss-HRP, which is a glycosylated protein secreted into the extracellular space. HeLa-ss-HRP were transfected with arrayed siRNA in a 96 well plate. At 72 h after transfection, we collected the supernatant, lysed the cells and assessed HRP by chemiluminescence. Knockdown that led to a decrease in the ratio of supernatant luminescence to cell lysate luminescence indicated genes that were important for glycoprotein secretion. Knockdown of 92 of the genes screened resulted in less secretion of HRP (Figure 2A). Positive controls also resulted in less HRP secretion, as expected (Figure 2A, B). The 92 genes validated by the siRNA screen are listed in Figure 2B and 2C. Of these hits, 55 were not annotated with GO_Slim terms related to secretion or protein transport; 22 of these had no GO_Slim annotations and 6 had no GO annotations at all (Figure 2C).

Further screening revealed many genes with altered glycoprotein secretion also had a fragmented Golgi apparatus

To further probe how the identified genes affect glycoprotein secretion, the 92 genes identified in the HRP screen were further analysed for changes in Golgi apparatus morphology using the same siRNA knockdown. At 72 h after siRNA transfection, cells were fixed and analysed by immunofluorescence, using an antibody against GM130, a marker of cis-Golgi membranes. Images were collected and classified as having fragmented or intact cis-Golgi using the machine learning platform within CellProfiler, as shown in Figure 3A and 3B (raw results are provided in S6, Underlying data).8 Many of the silenced genes resulted in an increase in fragmented cis-Golgi compared to the control (~20%). Genes with more than the median percentage of cells with fragmented Golgi are shown in Figure 3C, and all genes are shown in Figure E1 (see Extended data).9 Based on having unknown functions in secretion, five genes from the top half of these hits were chosen to further investigate the mechanism by which these hits lead to a secretion defect: GPR161, TMEM220, FAM98B, FAM102B and MXRA7. We confirmed that the knockdown of these five genes
Horseradish peroxidase (HRP) screen to identify genes important for secretion. Approximately 400 genes were screened in an arrayed siRNA knockdown format. (A) Mean of the normalised luminescence for both cell lysate and supernatant signals from two independent replicates. ~400 genes were screened; those with significant divergence from control siRNAs, as identified by the ROUT method, are indicated by a green cross (x). Twelve genes known to be involved in secretion or protein trafficking were included in the screen as positive controls, indicated by a blue plus (+); these known controls were also identified as hits, validating the statistical method used here. (B, C) Mean values for normalised luminescence for cell lysate and supernatant (SN) signals of the 92 hits identified. Here these hits are shown on a white-red scale, where darker red indicates a greater secretion defect. The generic GO_Slim was used to categorise hits as related to protein transport, unrelated to protein transport or not annotated. (B) A gene was defined as related to protein transport if it was annotated with any of the GO_Slim annotations transport (GO:0006810), transmembrane transport (GO:0055085) or vesicle-mediated transport (GO:0016192). (C) Genes unrelated to protein transport or not annotated by GO_Slim terms represent novel hits involved in protein secretion. Of the genes with no GO_Slim annotations, genes with no GO annotations at all are indicated in italics. Genes defined as not related to protein transport have other annotations in the generic GO_Slim.

Subcellular localisation of new regulators of glycoprotein secretion

Given the poor characterisation of GPR161, TMEM220, FAM98B, FAM102B and MXRA7 in the literature and the limited resources available to study their localisation, we obtained cDNA constructs of each of these gene fused to a FLAG-tag, to study the localisation of the protein inside the cells (Figure 4). HeLa cells were transiently transfected with cDNA, then fixed 24 h after transfection. Fixed cells were immunostained for FLAG and either calnexin or TGN46, markers of the ER and the Golgi, respectively. GPR161 localised to the Golgi, as seen by its co-localisation with TGN46 (Figure 4A). A gene was defined as related to protein transport if it was annotated with any of the GO_Slim annotations transport (GO:0006810), transmembrane transport (GO:0055085) or vesicle-mediated transport (GO:0016192). (C) Genes unrelated to protein transport or not annotated by GO_Slim terms represent novel hits involved in protein secretion. Of the genes with no GO_Slim annotations, genes with no GO annotations at all are indicated in italics. Genes defined as not related to protein transport have other annotations in the generic GO_Slim.
Figure 3. Further secondary screen for altered Golgi morphology. (A) Workflow of Golgi morphology screen. (B) Training set used to train the CellProfiler Analyst (CPA) classifier to distinguish between fragmented and intact Golgi. Using this training set, sensitivity was 77% for fragmented Golgi class and 82% for the intact Golgi class. Examples of control and test images classified using CPA are also shown. Cells with fragmented Golgi are labelled with 1; cells with intact Golgi are labelled with 2. (C) Percentage of cells with fragmented Golgi for the top 48 hits from tertiary screen. Hits are arranged alphabetically and coloured by cell count, with darker blue spots representing more confluent wells. Five of these hits were further characterised, indicated with blue rectangles. (D) Immunostaining of HeLa cells (original magnification 20x) treated with siRNA to knockdown each of the five genes indicated above the images. Cells were stained with the antibodies against the proteins indicated in green or red on the left. For all images, DAPI staining is shown in blue.
Figure 4. Localisation study for new regulators of glycoprotein secretion. Fluorescence microscopy images of HeLa cells expressing a FLAG-tagged cDNA construct show each protein’s localisation by co-staining with either an ER marker, calnexin, or a Golgi marker, TGN46. In the merged images, FLAG staining is shown in green and calnexin or TGN46 staining is shown in red. The subcellular localisation of each protein construct is indicated in green on the cell diagrams. Darker shades of green are used to indicate the most prominent location if the construct localises to more than one compartment. A–E show expression of FLAG-tagged GPR161 (A), TMEM220 (B), MXRA7 (C), FAM98B (D) and FAM102B (E). Original magnification 20x.

However, it is important to note that the overexpression of these FLAG-tagged constructs may not reflect the endogenous protein localisation, as some dominant negative effect might happen when using the cDNA construct. We believed this was the case for TMEM220, as the TGN46 immunostaining seems compromised in the transfected cells (Figure 4B). It was therefore important to validate the localisation of the protein using specific antibodies. We studied the localisation of the endogenous proteins GPR161 and TMEM220 and confirmed that GPR161 localised mainly in the Golgi (Figure 5Ai). This was further demonstrated using siRNA against GPR161; here the Golgi localisation of GPR161 disappeared (Figure 5Bi). However, endogenous TMEM220 localised to the Golgi (Figure 5Aii), in contrast to the cDNA overexpression showing an ER localisation. This Golgi residence was similarly confirmed using siRNA (Figure 5Bii). It is therefore likely that the overexpression of TMEM220 causes a perturbation in the trafficking of proteins from the ER to the Golgi.

GPR161 is a novel Golgi resident protein involved in protein secretion

Our study shows that GPR161 is a new Golgi-resident protein. To understand its role in secretion, we used the BioPlex network, a resource of proteins shown to interact by affinity purification-mass spectrometry, to look at its interacting partners. Interestingly, the BioPlex network shows that GPR161 interacts with golgin A5 (also known as golgin 84). Golgin A5 is a coiled-coil membrane protein that plays a role in intra-Golgi vesicle capture and contributes to maintaining Golgi morphology, likely by its interaction with Rab1A. We showed that golgin A5 and GPR161 colocalised (Figure 5C), and the knockdown of GPR161 decreased the colocalisation between golgin A5 and TGN46 (Figure 5D). This appears to be specific...
Figure 5. GPR161 and TMEM220, two novel Golgi-resident proteins involved in protein secretion, regulate glycoprotein secretion by different mechanisms. (A) Colocalisation microscopy shows that both (i) GPR161 and (ii) TMEM220 colocalise with TGN46 and GM130, two Golgi markers, and not with calnexin, a marker of the ER. (B) siRNA knockdown of (i) GPR161 or (ii) TMEM220 demonstrates that the antibodies used to detect these endogenous proteins only specifically detect protein at the Golgi. (C) GPR161-FLAG (red) colocalises with golgin A5 by microscopy. (D) Microscopy shows that knockdown of both GPR161 and TMEM220 lead to Golgi fragmentation seen by the TGN46 staining, but only GPR161 knockdown results in less colocalisation of golgin A5 and TGN46. Quantification of this change in colocalisation, measured by Pearson’s coefficient, shows that GPR161 knockdown cells have significantly less colocalisation than control cells (***p < 0.001), but there is no significant difference in colocalisation between control cells and TMEM220 knockdown cells (p = 0.302). Original magnification 20x.
to GPR161, since the knockdown of TMEM220, which we also found localises to the Golgi, did not affect golgin A5-TGN46 colocalisation, showing that Golgi fragmentation alone does not change golgin A5 localisation to the Golgi (Figure 5D). These data suggest that GPR161 may serve to recruit golgin A5 to the Golgi membrane.

Discussion

Here we identified novel genes involved in glycoprotein secretion using a combination of pooled CRISPR screening and siRNA screening. This work expands on our results from a previous CRISPR screen measuring cell-surface galectin-3, which had identified a number of regulators of glycosylation and protein trafficking; however, most of those hits had had well-known functions\(^\text{34}\). Although galectin-3 itself is unconventionally secreted, this type of screen should primarily identify genes responsible for the transport of glycoproteins to the cell surface, as secreted galectin-3 can be transferred between cells\(^\text{34,40}\). Here, we sought to build on the findings of our previous screen by using galectin-3 to identify novel proteins with roles in glycoprotein secretion. We used the improved Brunello sgRNA library\(^\text{24}\) rather than GeCKOv2 library, and an altered cell sorting strategy which would allow more hits through cell sorting initially, in order to increase the number of true positives in later populations. The Brunello library is an optimised library for the human genome, which was designed to increase the percentage of active guides while reducing off target effects compared to other libraries\(^\text{24}\). Furthermore, here we analysed populations at all stages of cell sorting rounds performed, rather than only the final sorted population.

Overall, our data suggest that the enhanced cell sorting strategy we employed here does improve results. While there is little enrichment visible by anti-galectin-3 staining in the earlier sorted populations, deep sequencing showed that enrichment had taken place. Many of the hits enriched in the first sorted population, N1, localise to the ER and the plasma membrane; later populations had fewer hits localised to the ER. This is likely due to problems with cell survival; over the extended time period and stress derived from the four sorts, cells with ER defects may be less able to survive. Enrichment of two distinct galectin-3 negative populations was visible by flow cytometry after the third round of cell sorting, in population N3. The most negative population within N3 consisted of cells that had little or no galectin-3 bound to the cell surface but were still able to secrete galectin-3 into the supernatant, so the excess of extracellular galectin-3 could bind to both the mid-negative population and the unaffected population of cells. Combined with the higher effective concentration of anti-galectin-3 antibody during staining, this meant that the unaffected population appeared to have more galectin-3 staining after earlier sorts. Across all sorted populations, the enrichment of many hits that are known to be in secretory and glycosylation pathways provides an initial validation of the success of the CRISPR screen. In comparison to our previous screen, we identified more hits known to have roles in the maturation or secretion of glycoproteins; moreover, we found a much higher number of genes not known to have such roles.

Due to the large number of hits identified by the MaGECK algorithms, we selected hits to be taken forward for secondary screening for protein secretion. Via this screening method, we identified 92 hits that result in a secretion defect, of which 55 are not annotated with GO terms related to secretion. The 92 hits validated for secretion represent approximately one quarter of the hits screened, highlighting the importance of secondary screening after a CRISPR screen due to the high chance of false positives. However, the fact that 55 of the validated hits have previously unknown or unclear functions in secretion demonstrates the power of this screening strategy.

To further validate these hits, we investigated Golgi morphology. There was a clear increase in the percentage of cells with Golgi fragmentation for many of the hits. As siRNA knockdown efficiency was not quantified for each gene, the percentage of cells with fragmented Golgi does not give a definitive ranking of the scale of the effect each gene has on protein secretion. Additionally, while the presence of fragmented Golgi gives a reason for the altered secretion and therefore validates both the CRISPR screen and HRP assay results, it does not explain how each individual gene product contributes to protein secretion. As such, we selected five hits with little known about their function in protein secretion to investigate further. Most of these had very strong phenotypes in both assays, such as MXRA7, but some had a weaker, yet still significant, phenotype, including GPR161: we studied this selection in order to validate the full list of genes as a resource for further investigation.

Among the five hits that we studied for further mechanistic insight, GPR161 and TMEM220 localised to the Golgi, whereas MXRA7 localised to the ER. FAM98B and FAM102B localised to the cytosol or the plasma membrane. Further studies will be required to fully understand how each gene regulates protein secretion. Interestingly, a recent study has shown the importance of the extracellular matrix (ECM) in regulating Golgi organisation and function via the activation of ARF1\(^\text{41}\). MXRA7, a component of the ECM, might play a similar role. Little is known about FAM98B and FAM102B, but FAM102B shows a clear localisation at the plasma membrane, so it could regulate protein secretion through an identified signalling pathway. FAM98B shows cytosolic and nuclear localisation, and interacts with other such proteins to form a complex involved in shuttling RNA between the nucleus and cytoplasm\(^\text{42}\), suggesting that FAM98B may affect protein secretion by a transcriptional route.

Our further investigation of the two proteins that localised to the Golgi, TMEM220 and GPR161, suggests that they regulate Golgi morphology by different mechanisms. TMEM220 is a transmembrane protein that has been shown to interact with both actin and testis-specific glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in the BioPlex network\(^\text{13,14}\). Actin, and the cytoskeleton in general, is well known to contribute to protein trafficking along the secretory pathway; for example, it is recruited to the Golgi to by a complex of SPCA1 and active cofillin, where it is suggested to form a membrane domain required...
to initiate sorting of secretory cargo. It is possible that TMEM220 acts as an anchor for actin on the Golgi membrane. This possibility needs to be further investigated using in vitro experiments. Alternatively, TMEM220 could affect protein secretion via an interaction with GAPDH, which has recently been implicated in protein secretion via the inhibition of COPI vesicle biogenesis.

GPR161 is a G-protein-coupled receptor (GPCR) that is involved in neural tube development and acts as a regulator of cell signalling pathways, including Shh signalling, protein kinase A (PKA) signalling, retinoic acid signalling and Wnt signalling. This was a particularly interesting hit as it has recently become clear that GPCRs function at membranes other than the plasma membrane, and previous work has suggested that a Golgi-resident GPCR regulates transport from the Golgi, although the specific GPCR involved remains unknown. Our results showing that GPR161 is both localised to the Golgi and involved in regulation of Golgi morphology and glycoprotein trafficking with this emerging idea that GPCRs can regulate protein trafficking. The BioPlex network for GPR161 shows an interaction with golgin A5, as well as with five PKA subunits; other work has also demonstrated an interaction between GPR161 and PKA. The interaction with PKA subunits is interesting, as a PKA signalling pathway has previously been shown to regulate retrograde transport from the Golgi to the ER, which indirectly affects anterograde traffic. However, previous work found that PKA regulatory subunits bind to GPR161 results in its transport to the plasma membrane to signal through PKA. Here, we did not observe any localisation of either overexpressed or endogenous GPR161 at the plasma membrane, suggesting that a different mechanism may be important here. Furthermore, our data suggest that the interaction between GPR161 and golgin A5 is important for maintenance of the Golgi architecture and function, and we propose that GPR161 may act to recruit golgin A5 to the Golgi. To confirm this, further experiments involving mutated forms of GPR161 and golgin A5 will have to be performed.

In summary, here we describe an optimised CRISPR screening strategy that successfully identifies new regulators of glycoprotein secretion. Our secondary screening validated 55 hits not previously known to be directly involved in protein secretion; many of these hits also regulate Golgi morphology. We hope that these validated hits can serve as a resource for other researchers investigating protein secretion and Golgi morphology. We also highlight GPR161, a particularly interesting protein given that Golgi-localised GPCRs have recently been implicated in protein trafficking. We find that it is a novel Golgi-localised protein that appears to interact with golgin A5 in order to maintain Golgi structure.

Data availability

Underlying data

Raw sequencing files from deep sequencing of the screened populations on Gene Expression Omnibus, Accession number GSE133692: https://identifiers.org/geo/GSE133692.

Apollo: Research data supporting ‘Genome-wide CRISPR screening identifies new regulators of glycoprotein secretion’. https://doi.org/10.17863/CAM.4040

This project contains the following underlying data:
- S1.xlsx (sgRNA counts of unsorted and sorted population from the CRISPR screen)
- S2.xlsx (MaGECK [version 0.5.7] analysis of sgRNA counts from the CRISPR screen. Both MaGECK-MLE and MaGECK-RRA results are shown. False discovery rates [FDR] from this table were used to create Figure 1C–E)
- S3.zip (raw FCS files from flow cytometry staining of sorted samples, used to create Figure 1B)
- S4.xlsx (raw chemiluminescence data, used to create Figure 2)
- S5.zip (unedited image files used in Figure 3D, Figure 4 and Figure 5)
- S6.xlsx (data output from Cell Profiler, showing total number of cells identified per image and number of cells classified as having fragmented or intact Golgi)

Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).

Extended data

Apollo: Research data supporting ‘Genome-wide CRISPR screening identifies new regulators of glycoprotein secretion’. https://doi.org/10.17863/CAM.4040

This project contains the following extended data:
- E1.pdf (all hits from the secondary screen for Golgi morphology, top hits of which are shown in Figure 3C)
- E2.xlsx (sequence of P5 primers used for PCR amplification of sgRNA)
- E3.xlsx (sequence of P7 primers used for PCR amplification of sgRNA)
- E4.xlsx (details of the siGenome pooled siRNA library used in secondary screening)

Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).

Grant information

This work was supported by a Wellcome Trust PhD studentship for S.J.P. [109152], a Wellcome Trust Strategic Award [100574], the Medical Research Council Metabolic Diseases Unit [MRC_MC_UU_12012/5], the Isaac Newton Trust/Wellcome
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Acknowledgments
We thank Paul Lehner for shLe cells, Vivek Malhotra for HeLa-ss-HRP cells, David Root and John Doench for the Brunello library, Marcella Ma, Brian Lam and Giles Yeo for valuable help and advice with the gRNA sequencing, Matt Castle for advice on statistical analysis, and James Smith and Greg Strachan for technical assistance with the Opera Phenix.

References

27. Reverse siRNA transfection | Peikmans Lab. Reference Source


Open Peer Review

Current Peer Review Status: ❓ ❓

Version 1

Reviewer Report 28 August 2019

https://doi.org/10.21956/wellcomeopenres.16623.r36252

© 2019 Stephens D. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

David Stephens 📘

School of Biochemistry, Faculty of Life Sciences, University of Bristol, Bristol, UK

This is an interesting manuscript that applies CRISPR gene editing approaches to screen for components of the glycoprotein secretion machinery. It appears to be carefully conducted with appropriate analysis applied to the screen. I am not an expert in that area and so cannot comment on the design, execution, or analysis of the screen further.

The results are clearly presented and some key "hits" defined. I would have liked to have read more about the overlap between the current work and previous efforts e.g. whole genome RNAi screens in mammalian cells and flies¹,²,³. Particularly given the previous use of ssHRP as a reporter.

Fundamentally the screen is really testing those genes required for localization of galectin-3 to the cell surface, this is not quite the same as a global analysis of glycoprotein secretion. Perhaps validation with other lectins, or of specific glycoproteins, or even an unbiased glycoproteomics approach might have been appropriate - at least for the "hits" that were worked up. Really, I would have liked to see some analysis of other endogenous glycoproteins as well as non-glycosylated secretory proteins. In particular, it is not clear to me whether the effects seen are indeed general or specific to galectin-3.

The analysis of five of the key "hits" is quite preliminary but the work is carefully conducted and nicely presented. This provides some framework for others to build on these data. The link between defects in glycoprotein secretion and Golgi organization are not really explored and this could have been built on to provide more insight.

A fundamental limitation for me is that none of the validation work has been done in any system other than HeLa cells. Given the literature on the role of GPR161 in cilia⁴, one might have hoped to see some work-up done in ciliated cells.

I expect that this will stand alone as a useful data resource and can certainly be built on by others.

Specific comments:
RNAi efficacy (important for Figure 5) is not validated anywhere that I could see.

The colocalization analysis is limited. GolginA5 and TGN46 should not overlap significantly as they localize to distinct parts of the Golgi/TGN (5D), therefore I have doubts over the robustness of this readout. In Figure 5C colocalization of GPR161 and GolginA5 does not appear robust to me and is not quantified. The images shown are low resolution and more detailed analysis is warranted. Nocodazole treatment of cells to scatter the stacked Golgi would be useful here.

The integrity of the microtubule network should be checked as disruption of this could result in altered Golgi morphology (but not likely to secretion per se). The two phenotypes might be unconnected.

The conclusion that GPR161 might recruit GolginA5 is premature. The data do not provide sufficient support for this.

References

Is the work clearly and accurately presented and does it cite the current literature? Partly

Is the study design appropriate and is the work technically sound? Yes

Are sufficient details of methods and analysis provided to allow replication by others? Yes

If applicable, is the statistical analysis and its interpretation appropriate? Yes

Are all the source data underlying the results available to ensure full reproducibility? Yes

Are the conclusions drawn adequately supported by the results? Partly
Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Cell biology, membrane traffic and cytoskeletal dynamics.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Reviewer Report 27 August 2019

https://doi.org/10.21956/wellcomeopenres.16623.r36185

© 2019 Farhan H. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Hesso Farhan
Institute of Basic Medical Sciences, Department of Molecular Medicine, University of Oslo, Oslo, Norway

The work by Popa and colleagues from the Moreau group reports on the identification of new regulators of glycoprotein secretion using a CRISPR screen. The manuscript is written well and is easy to follow. Most of the data are of strong quality and therefore, I am supportive of the indexing of this work. I have a few concerns that could be easily addressed by a revision.

1. The title implies that the paper identifies regulators of glycoprotein secretion. How sure are the authors that these new proteins regulate glycoprotein trafficking, and not general trafficking? If they want to maintain the prefix glyco-, then they should show that non-glycosylated proteins such as albumin are not affected.

2. The authors use the term “Golgi fragmentation”, but this is not what I see. In many cases, the Golgi is simply aberrant in shape (stretched, or extended). Is it possible to revisit the data to show quantification of Golgi “fragments”? I think it is safer to use the term “aberrant Golgi structure”. The authors could use the Golgi compactness index developed originally by Fred Bard (2003).

3. It is hard to appreciate the effects on ERES, with the magnification and image quality the authors use. In my experience, a 20X magnification does not permit reliable judging of ERES. The authors should do better ERES imaging and quantification for the 2-3 most important hits. Especially for TMEM220, which they consider a regulator of ER-Golgi trafficking. This needs to be experimentally supported.

4. The authors state/conclude that GRP161 serves to recruit GolginA5 to the Golgi. I don’t think that the data support this claim. A similar perturbation of GolginA5 staining is seen with TMEM220. Could these not be simply a reflection of a distorted Golgi structure?

5. General comment: the work does not compare the results to previous screens by Rainer Pepperkok¹, Hesso Farhan² and Fred Bard³. I am not sure why the authors chose to ignore this previous work, despite its obvious relevance to the current paper. Not only should these three papers be cited, but a comparison of the hits should be made.
References

Is the work clearly and accurately presented and does it cite the current literature?
No

Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?
Yes

If applicable, is the statistical analysis and its interpretation appropriate?
I cannot comment. A qualified statistician is required.

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Membrane trafficking, Signal transduction, COP II, Golgi, Cell migration, Rho GTPases, KInases

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.